Back to top

Image: Bigstock

Strength Seen in Butterfly Network (BFLY): Can Its 8.9% Jump Turn into More Strength?

Read MoreHide Full Article

Butterfly Network, Inc. (BFLY - Free Report) shares rallied 8.9% in the last trading session to close at $5.29. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 23% gain over the past four weeks.

Butterfly Network scored a strong price increase on investors’ optimism surrounding the company’s impending first quarter 2026 financial results, which is slated to release on April 30. Per the Zacks Consensus Estimate, the company’s revenues are expected to increase 22.5% year over year. Loss per share is pegged at 4 cents for the first quarter, indicating 33.3% year over year improvement. 

This company is expected to post quarterly loss of $0.04 per share in its upcoming report, which represents a year-over-year change of +33.3%. Revenues are expected to be $26 million, up 22.5% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For Butterfly Network, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on BFLY going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Butterfly Network belongs to the Zacks Medical Info Systems industry. Another stock from the same industry, Clover Health Investments, Corp. (CLOV - Free Report) , closed the last trading session 0.5% higher at $2.16. Over the past month, CLOV has returned 14.4%.

Clover Health Investments' consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.07. Compared to the company's year-ago EPS, this represents a change of +40%. Clover Health Investments currently boasts a Zacks Rank of #3 (Hold).

Zacks' 7 Best Strong Buy Stocks (New Research Report)

Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.

Click Here, It's Really Free

Published in